Alterations of amylase secretion in the chronically reserpinized rat: an acetylcholine-mediated phenomenon.
Chronic reserpine treatment of animals, an experimental model for cystic fibrosis (CF), results in generalized exocrinopathy, impaired secretion, and decreased pancreatic content of amylase. However, the mechanisms of altered acinar pancreatic function in both CF patients and reserpine-treated rats are still unknown. The present study was designed to investigate the secretory response of the rat pancreas after reserpine treatment. Rats were given reserpine (1 mg kg-1 day-1 ip) or vehicle, and killed 2, 4, or 7 days later. To distinguish between specific effects of reserpine and those related to secondary malnutrition caused by the drug, secretory response of a group of pair-fed animals to reserpine was also investigated. During reserpine treatment, body weight and food intake were significantly reduced from the 2nd day on. Amylase release from dispersed pancreatic acini, prepared from control pair-fed and from reserpine-treated rats were used to evaluate functional secretory capacity. After 7 days, both chronic reserpine and pair-feeding significantly decreased pancreatic amylase concentration to 75 and 50% of controls, respectively. Reserpine caused desensitization of the pancreatic acini secretory response to carbamylcholine, without altering maximal amylase release. Desensitization occurred gradually and reached a maximum after 7 days. Secretory responses to caerulein and to the phorbol ester 12.0-tetradecanoyl phorbol-13 acetate (TPA) were not altered. These findings indicate that desensitization of amylase release after reserpine was specific to this muscarinic agonist. It may result from increased endogenous acetylcholine release in the course of treatment.
Benrezzak
O
O
Département de Biologie, Faculté des Sciences, Université de Sherbrooke, Québec, Canada.
Bérubé
F L
FL
Morisset
J
J
D000109:Acetylcholine / Q000378:metabolism / Q000502:physiology*; D000681:Amylases / Q000378:metabolism*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002217:Carbachol / Q000494:pharmacology; D002108:Ceruletide / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000139:chemically induced / Q000503:physiopathology; D004195:Disease Models, Animal; D004435:Eating / Q000187:drug effects; D008297:Male; D010179:Pancreas / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D012110:Reserpine / Q000633:toxicity*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors
D002108:Ceruletide; D012110:Reserpine; D002217:Carbachol; D000681:Amylases; D000109:Acetylcholine; D013755:Tetradecanoylphorbol Acetate